Regulator says too many drugmakers chasing same cancer strategy   Reuters reports that Dr. Richard Pazdur, who heads the Food and Drug Administration’s office of oncology products, believes that?too many companies are focused on PD-1 inhibitors for?cancer immunotherapy. Whereas PD-1 inhibitors show promise for remarkable efficacy, Dr. Pazdur is reportedly concerned that?too many companies are[…]